AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $57.25
  • 50 Day Moving Average: $4464.19
  • 200 Day Moving Average: $4650.98
  • 52-Week Range: £12,650,000 - GBX 3,680
  • Trailing P/E Ratio: 16.56
  • P/E Growth: 4.20
  • Market Cap: $57.81B
  • Outstanding Shares: 1,265,000,000
Additional Links:

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 4 Sell Ratings, 9 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: GBX 4,953.82

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
DateFirmActionRatingPrice TargetDetails
2/20/2017Beaufort SecuritiesReiterated RatingHoldView Rating Details
2/20/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
2/17/2017Goldman Sachs Group, Inc. (The)Set Price TargetSellGBX 3,900View Rating Details
2/17/2017Jefferies Group LLCBoost Price TargetBuyGBX 4,800 -> GBX 5,250View Rating Details
2/16/2017Shore CapitalReiterated RatingSellGBX 4,595View Rating Details
2/13/2017Liberum CapitalLower Price TargetBuyGBX 5,200 -> GBX 5,100View Rating Details
2/8/2017BNP ParibasReiterated RatingNeutralGBX 5,300View Rating Details
2/7/2017HSBC Holdings plcLower Price TargetHoldGBX 4,700 -> GBX 4,500View Rating Details
2/6/2017Deutsche Bank AGLower Price TargetBuyGBX 6,000 -> GBX 5,500View Rating Details
2/3/2017Credit Suisse GroupReiterated RatingUnderperformGBX 4,000View Rating Details
1/23/2017InvestecInitiated CoverageHoldGBX 4,600View Rating Details
1/23/2017Kepler Capital MarketsReiterated RatingBuyGBX 5,000View Rating Details
1/18/2017Morgan StanleySet Price TargetBuyGBX 5,600View Rating Details
1/9/2017Bryan, Garnier & CoReiterated RatingBuyGBX 5,250View Rating Details
12/6/2016Berenberg BankReiterated RatingBuyGBX 5,500View Rating Details
11/16/2016Societe GeneraleReiterated RatingBuyGBX 6,500View Rating Details
11/7/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
10/19/2016Sanford C. BernsteinSet Price TargetNeutralGBX 5,333View Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
4/25/2016Barclays PLCReiterated RatingEqual WeightGBX 5,000View Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details
4/9/2015Redburn PartnersUpgradeBuyView Rating Details
(Data available from 2/20/2015 forward)


Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by


Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $3.71 EPS


Dividend History for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)


Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline logoAnalyst Activity – Beaufort Securities Reiterates Hold on AstraZeneca plc (LON:AZN) - Market Exclusive (LON:AZN) - February 20 at 3:42 PM
News IconAstraZeneca licenses Cancer Drug Zoladex to TerSera for the US, Canada (LON:AZN) - February 20 at 9:33 AM logoAstraZeneca sells commercial rights to Zoladex cancer treatment (LON:AZN) - February 20 at 9:33 AM logo3 FTSE 100 stocks I’d never sell (LON:AZN) - February 20 at 9:33 AM logo[$$] May orders officials to examine case for intervening in Unilever bid (LON:AZN) - February 19 at 9:47 AM logoAstraZeneca : Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook (LON:AZN) - February 18 at 3:42 PM
News IconAre Analysts Optimistic About Where Astrazeneca PLC (NYSE:AZN) is Heading? - Winfield Review (LON:AZN) - February 18 at 5:31 AM logoChina MediTech And AstraZeneca Plc (NYSE: AZN) To Present Savolitinib Phase II Results At The Genitourinary ... - Market Exclusive (LON:AZN) - February 16 at 8:40 AM logoValeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis (LON:AZN) - February 16 at 8:40 AM
News IconChina MediTech And AstraZeneca PLC (ADR) (AZN) To Present Savolitinib Phase II Results At The Genitourinary Cancers Symposium 2017 (LON:AZN) - February 15 at 10:27 AM logoAstrazeneca PLC (AZN) Ex-Dividend Date Scheduled for February 15, 2017 - Nasdaq (LON:AZN) - February 14 at 3:22 PM logoChi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium (LON:AZN) - February 14 at 3:22 PM logo[$$] Executive pay needs a radical new structure (LON:AZN) - February 14 at 3:22 PM
News IconLarge Cap Drug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) (LON:AZN) - February 8 at 8:57 PM logoAre shares in GlaxoSmithKline plc now in bargain territory? (LON:AZN) - February 8 at 3:55 PM logoAre shares in GlaxoSmithKline plc now in bargain territory? (LON:AZN) - February 8 at 3:55 PM
News IconTrading Spotlight on Shares of AstraZeneca PLC (AZN.L) - Rives Journal (LON:AZN) - February 7 at 9:44 PM
News IconDrug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) Position of the day (LON:AZN) - February 7 at 4:42 PM
News IconACADIA Pharmaceuticals (ACAD) Buyout: Why The AstraZeneca (AZN) Rumor Matters - BNL Finance (press release) (registration) (blog) (LON:AZN) - February 6 at 8:52 PM
News IconStocks in Frontline Trades' Choice: Ixia (NASDAQ:XXIA), AstraZeneca PLC (NYSE:AZN) - Street Wise Report (press release) (blog) (LON:AZN) - February 3 at 3:55 PM logoAstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales - Yahoo Finance (LON:AZN) - February 3 at 3:55 PM logoAstraZeneca PLC : Announces Full-Year and Q4 2016 Results (LON:AZN) - February 2 at 8:51 PM logoAstraZeneca Plc (AZN) Q4 2016 Results - Earnings Call Transcript (LON:AZN) - February 2 at 8:51 PM logoEdited Transcript of AZN.L earnings conference call or presentation 2-Feb-17 12:30pm GMT (LON:AZN) - February 2 at 8:51 PM
News IconWhat are the Technical Charts Saying About AstraZeneca PLC (AZN) - Springdale Times (LON:AZN) - January 31 at 2:58 AM
News IconAstraZeneca PLC (ADR) (AZN) Wins A Six Months Paediatric Exclusivity Approval Of Its Symbicort (LON:AZN) - January 30 at 12:24 PM logoAstraZeneca’s Symbicort Gets Pediatric Exclusivity (AZN) (LON:AZN) - January 27 at 4:57 PM
News IconGoldman Sachs Indicates Potential -8.69% Decrease In Shares Of AstraZeneca PLC (LON:AZN) - January 26 at 1:56 AM logoCancer, hepatitis treatments set for boost as China overhauls drugs list (LON:AZN) - January 26 at 1:56 AM
News IconShares of Astrazeneca PLC (NYSE:AZN) Sees Large Inflow of Net Money Flow - Highland Mirror (LON:AZN) - January 24 at 9:20 PM logoAstraZeneca Plc breached its 50 day moving average in a Bearish Manner : AZN-GB : January 23, 2017 (LON:AZN) - January 24 at 4:18 PM logoAstraZeneca Plc – Value Analysis (LONDON:AZN) : January 24, 2017 (LON:AZN) - January 24 at 4:18 PM logoUPDATE 1-Synergy wins U.S. approval for constipation drug (Jan 19) (LON:AZN) - January 24 at 4:18 PM
News IconStock Overview: Moving Average Check on AstraZeneca PLC (AZN.L) - Springdale Times (LON:AZN) - January 24 at 1:57 AM logoAstraZeneca : Big pharma perspective on adaptive clinical trial designs (LON:AZN) - January 23 at 3:54 PM logoInteresting AZN Call Options For March 17th (LON:AZN) - January 23 at 3:54 PM
News IconChart Inspection on Shares of AstraZeneca PLC (AZN.L) - Springdale Times (LON:AZN) - January 20 at 3:00 AM
News IconThe Hunting plc (HTG) Price Target Raised to GBX 650 (LON:AZN) - January 19 at 9:58 PM
News IconAstraZeneca plc (ADR) (AZN) MYSTIC Change Incrementally ... - Smаrt Stоck Nеws (LON:AZN) - January 19 at 9:58 PM logoAstraZeneca's Catch-Up Strategy is Falling Behind (LON:AZN) - January 18 at 9:27 PM
News IconAnalysts Take: Astrazeneca PLC (NYSE:AZN) Projected Earnings & Price Targets - Aiken Advocate (LON:AZN) - January 16 at 11:19 AM logoAdding AstraZeneca To Our Model Portfolio - Seeking Alpha (LON:AZN) - January 13 at 4:20 PM
News IconWill The Needle Move For Astrazeneca PLC (NYSE:AZN) Shares This Earnings Season? - Wall Street Beacon (LON:AZN) - January 12 at 3:54 PM logoMarch 3rd Options Now Available For AstraZeneca (LON:AZN) - January 12 at 12:16 PM
News IconHigh Market Cap Stock of the Day – AstraZeneca PLC (NYSE:AZN) (LON:AZN) - January 10 at 3:51 PM logoCan AstraZeneca (AZN) Be a Solid Choice for Value Investors? (LON:AZN) - January 10 at 3:51 PM logo[$$] Chance for an agile new drug approval system (LON:AZN) - January 9 at 9:57 PM
News IconAstraZeneca plc (ADR) (AZN): Merill Lynch Analysts view on MYSTIC - Smаrt Stоck Nеws (LON:AZN) - January 4 at 8:56 PM
News IconTwo Stocks in Concentration: Seagate Technology plc (NASDAQ:STX), AstraZeneca PLC (NYSE:AZN) - The Newburgh Press (LON:AZN) - January 4 at 3:54 PM logoIs Neil Woodford’s favourite stock set to outperform in 2017? (LON:AZN) - January 4 at 3:54 PM


What is AstraZeneca plc's stock symbol?

AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?

AstraZeneca plc declared a dividend on Thursday, February 2nd. Stockholders of record on Thursday, February 16th will be given a dividend of GBX 150.20 per share on Monday, March 20th. This represents a dividend yield of 3.52%. The ex-dividend date is Thursday, February 16th. This is an increase from AstraZeneca plc's previous dividend of $68.70. The official announcement can be viewed at this link.

Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?

24 analysts have issued twelve-month price objectives for AstraZeneca plc's stock. Their forecasts range from GBX 3,650 to GBX 6,500. On average, they expect AstraZeneca plc's stock price to reach GBX 4,953.82 in the next year.

When will AstraZeneca plc announce their earnings?

AstraZeneca plc is scheduled to release their next quarterly earnings announcement on Thursday, April, 27th 2017.

How do I buy AstraZeneca plc stock?

Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of AstraZeneca plc stock cost?

One share of AstraZeneca plc stock can currently be purchased for approximately GBX 4,570.

Last Updated on 2/20/2017 by Staff